Chimerix shares surged more than 12 percent on Monday after reports surfaced that the Dallas, Texas patient diagnosed with Ebola last week would be treated with the company's experimental brincidofovir drug.
The drug received Emergency Investigational New Drug Applications (EINDA) from the U.S. Food and Drug Administration, the company said earlier.
Read MoreBracefor another Ebola patient in US: CDC chief
Chimerix is working closely with the FDA to finalize future trials to assess the safety and effectiveness of the drug in patients.